CSF3 and neutropenia: In PRODIGE 38 AMEBICA study, modified FOLFIRINOX showed the lower incidence of all grade 3–4 adverse events (72.8%) as well as neutropenia (20.7%) than those of our study probably due to the dose modification and the frequent use of primary prophylactic G-CSF.